The pharmacology of bisphosphonates and new insights into their mechanisms of action

Journal of Bone and Mineral Research

Volumn 14, Issue SUPPL. 2, 1999, Pages 53-65

  Russell, R Graham G ^a,d   Rogers, Michael J ^b   Frith, Julie C ^a,b   Luckman, Steven P ^a,b   Coxon, Fraser P ^a,b   Benford, Helena L ^b   Croucher, Peter I ^a   Shipman, Claire ^a   Fleisch, Herbert A ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c Univ of Sheffield Medical School ^*  (Switzerland)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE DERIVATIVE; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; EB 1053; ETIDRONIC ACID; HYDROXYAPATITE; IBANDRONIC ACID; INCADRONIC ACID; MEVALONIC ACID; NERIDRONIC ACID; NITROGEN; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; UNCLASSIFIED DRUG; ZOLENDRONIC ACID; [1 HYDROXY 2 (IMIDAZO[1,2 A]PYRIDIN 3 YL)ETHYLIDENE]BISPHOSPHONIC ACID;

APOPTOSIS; CALCIFICATION; CALCIUM METABOLISM; CONFERENCE PAPER; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; PRENYLATION; PROTEIN MODIFICATION; STRUCTURE ACTIVITY RELATION;

EID: 0032859149     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.5650140212     Document Type: Conference Paper

References (143)

1. Menschutkin N 1865 Ueber die Einwirkung des Chloracetyls auf phosphorige Saure. Ann Chem Pharm 133:317-320.
2. Smith R, Russell RGG, Bishop M 1971 Diphosphonates and Paget's disease of bone. Lancet 1:945-947.
3. Von Baeyer H, Hofmann KA 1897 Acetodiphosphorige Saure. Berichte Dtsch Chem Ges 20:1973-1978.
4. Blomen LJMJ 1995 Discovery and history of the non-medical uses of bisphosphonates. In: Bijvoet O, Fleisch HA, Canfield RE, Russell RGG (eds.) Bisphosphonates on Bone. Elsevier Science B.V., Amsterdam, pp. 111-124.
5. Fleisch H, Russell RGG, Bisaz S, Casey PA, Muehlbauer RC 1968 The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif Tissue Res 2(suppl.):10-10A.
6. Fleisch H, Neuman WF 1961 Mechanisms of calcification: Role of collagen, polyphosphates, and phosphatase. Am J Physiol 200:1296-1300.
7. Fleisch H, Bisaz S 1962 Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 203:671-675.
8. Fleisch H, Russell RGG, Straumann F 1966 Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212:901-903.
9. Fleisch H, Maerki J, Russell RGG 1966 Effect of pyrophosphate on dissolution of hydroxyapatite and its possible importance in calcium homeostasis. Proc Soc Exp Biol Med 122:317-320.
10. 3 in rats. Clin Sci 35:363-372.
11. Russell RGG, Hodgkinson A 1966 The urinary excretion of inorganic pyrophosphate by normal subjects and patients with renal calculus. Clin Sci 31:51-62.
12. Russell RGG 1965 Excretion of inorganic pyrophosphate in hypophosphatasia. Lancet ii:461-464.
13. Russell RGG, Bisaz S, Donath A, Morgan DB, Fleisch H 1971 Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta and other disorders of bone. J Clin Invest 50:961-969.
14. Francis MD, Russell RGG, Fleisch H 1969 Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165:1264-1266.
15. Fleisch H, Russell RGG, Francis MD 1969 Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262-1264.
16. Smith R, Russell RGG, Bishop M 1971 Diphosphonate and Paget's disease of bone. Lancet 1:945-947.
17. Russell RGG, Smith R, Preston C, Walton RJ, Woods CF 1974 Diphosphonates in Paget's disease. Lancet 1:894-898.
18. Delmas PD, Meunier PJ 1997 The management of Paget's disease of bone. N Engl J Med 336:558-566.
19. Diel IJ, Solomayer E-F, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G 1998 Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363.
20. Douglas DL, Russell RGG, Preston CJ, Prenton MA, Duckworth T, Kanis JA, Preston FE, Woodhead JS 1980 Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet 1:1043-1047.
21. Paterson AD, Kanis JA, Cameron EC, Douglas DL, Beard DJ, Preston FE, Russell RGG 1983 The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma. Br J Haematology 54:121-131.
22. Ralston SH, Gallacher SJ, Patel U, Fraser WD, Dryburgh FJ, Boyle IT 1989 Comparison of three bisphosphonates in cancer-associated hypercalcaemia. Lancet ii:1180-1182.
23. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock MB, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD 1996 Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488-493.
24. McCloskey EV, MacLennan ICM, Drayson M, Chapman C, Dunn J, Kanis JA 1998 A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haem 100:317-325.
25. Mundy GR, Yoneda T 1998 Bisphosphonates as anticancer drugs. N Engl J Med 339:398-400.
26. Fogelman I, Bessent RG, Turner JF, Citrin DL, Boyce IT, Greig WR 1978 The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med 19:270-275.
27. Francis MD, Fogelman I 1987 99mTc-diphosphonate uptake mechanisms on bone. In: Fogelman I (ed.) Bone Scanning in Clinical Practice. Springer Verlag, London, pp. 1-6.
28. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH 1990 Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271.
29. Watts NB, Harris ST, Genant HK, et al. 1990 Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79.
30. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriquez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443.
31. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Res Group. Lancet 348:1535-1541.
32. van Staa TP, Abenhain L, Cooper C 1998 Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheum 37:87-94.
33. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA 1997 Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382-387.
34. Saag KG, Emkey K, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman U, Delmas PD, Malice M-P, Czachur M, Daifotis AG 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292-299.
35. Miller PD 1998 Efficacy and safety of cyclical etidronate therapy in the long-term treatment of osteoporosis. Revs in Contemp Pharma 9:255-260.
36. Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut CH III 1997 Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 103:468-476.
37. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 33:947-952.
38. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246-1254.
39. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480.
40. Bijvoet O, Fleisch H, Canfield RE, Russell RGG (eds.) 1995 Bisphosphonates on Bone. Elsevier Science B.V., Amsterdam, The Netherlands.
41. Fleisch H 1997 Bisphosphonates in Bone Disease. From the Laboratory to the Patient, 3rd edn, The Parthenon Publishing Group, New York, NY, U.S.A.
42. Fleisch H 1998 Bisphosphonates: Mechanisms of action. Endocr Rev 19:80-100.
43. Ebetino FH, Francis MD, Rogers MJ, Russell RGG, 1998 Etidronate. Mechanisms of action of etidronate and other bisphosphonates. Revs Contemp Pharma 9:233-243.
44. Rogers MJ, Watts DJ, Russell RGG 1997 Overview of bisphosphonates. Cancer 80/8:1652-1669.
45. Russell RGG, Rogers MJ 1997 Introduction to bisphosphonates and the clinical pharmacology of alendronate. Br J Rheumatol 36(suppl):10-14.
46. Johnson S, Johnson FN (eds.) 1998 Etidronate in Osteoporosis. Revs in Contemp Pharm, Vol. 9.
47. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ 1994 Bisphosphonates: Structure-activity relationships and therapeutic implications. J Bone Miner Res 8:265-306.
48. Sietsema WK, Ebetino FH, Salvagno AM, Sevan JA 1989 Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exptl Clin Res 15:389-396.
49. Francis RM 1998 Oral Bisphosphonates in the treatment of osteoporosis: A review. Curr Ther Res 56:831-851.
50. Papapoulos SE 1995 Pharmacodynamics of bisphosphonates in man. In: Bijvoet O, Fleisch HA, Canfield RE, Russe RGG (eds.) Bisphosphonates on Bone. Elsevier Science B.V., Amsterdam, The Netherlands.
51. Jung A, Bisaz S, Fleisch H 1973 The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 11:269-280.
52. Russell RGG, Muhlbauer RC, Bisaz S, Williams DA, Fleisch H 1970 The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res 6:83-196.
53. Ebrahimpour A, Francis MD 1995 Bisphosphonate therapy in acute and chronic bone loss: Physical chemical considerations in bisphosphonate-related therapies. In: Bijvoet O, Fleisch HA, Canfield RE, Russell RGG (eds.) Bisphosphonate on Bones. Elsevier Science B.V., Amsterdam.
54. Fleisch HA, Russell RGG, Bisaz SM, Muhlbauer RC, Williams DA 1970 The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1:12-18.
55. Smith R 1995 Ectopic Calcification and Ossification. In: Bijvoet O, Fleisch HA, Canfield RE, Russell RGG (eds.) Bisphosphonate on Bones. Elsevier Science B.V., Amsterdam.
56. Schenk R, Merz WAM, Muhlbauer R, Russell RGG, Fleisch H 1973 Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (C12MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 11:196-214.
57. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P 1983 Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 35:87-99.
58. Flanagan AM, Chambers TJ 1989 Dichloromethylenebisphosphonate (C12MBP) inhibits bone resorption through injury to osteoclasts that resorb C12MBP-coated bone. Bone Miner 6:33-43.
59. Schenk R, Eggli P, Fleisch H, Rosini S 1986 Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38:342-349.
60. Gasser AB, Morgan DB, Fleisch HA, Richelle LJ 1972 The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci 43:31-45.
61. Reitsma PH, Bijvoet OLM, Verlinden-Ooms H, van der Wee-Pals LJA 1980 Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxy-propylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int 32: 145-157.
62. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700.
63. Trechsel U, Stutzer A, Fleisch H 1987 Hypercalcaemia induced with an arotinoid in thyroparathyroidectomised rats. A new model to study bone resorption in vivo. J Clin Invest 80:1679-1686.
64. Stutzer A, Fleisch H, Trechsel U 1988 Short and long term effects of a single dose of bisphosphonates on retinoid-induced bone resorption in thyroparathyroidectomised rats. Calcif Tissue Int 43:294-299.
65. Muhlbauer RC, Russell RGG, Williams DA, Fleisch H 1971 The effects of diphosphonates, polyphosphates and calcitonin on "immobilisation osteoporosis" in rats. Eur J Clin Invest 1:336-344.
66. Ferretti JL 1995 Effects of bisphosphonates on bone biomechanics. In: Bijvoet O, Fleisch HA, Canfield RE, Russell RGG (eds.) Bisphosphonate on Bones. Elsevier Science B.V., Amsterdam, The Netherlands.
67. Martodam RR, Thornton KS, Sica DA, D'Souza SM, Flora L, Mundy GR 1983 The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat Leydig cell tumor. Calcif Tissue Int 35:512-519.
68. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T 1995 Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:3551-3557.
69. Mundy GR, Yoneda T 1995 Facilitation and suppression of bone metastasis. Clin Orthop 312:34-44.
70. Mundy GR 1998 Bisphosphonates as anticancer drugs. N Engl J Med 339:398-400.
71. Muhlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H 1991 BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003-1011.
72. Papapoulos SE, Hoekman K, Lowik CWGM, Vermeij P, Bijvoet OLM 1988 Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res 4:775-781.
73. Goa KL, Balfour JA 1998 Risedronate. Drugs Aging 13:83-91.
74. Green JR, Mueller K, Jaeggi KA 1994 Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-751.
75. Ebetino FH, Bayless AV, Amburgey J, Ibbotson KJ, Dansereau S, Ebrahimpour A 1996 Elucidation of a pharmacore for the bisphosphonate mechanism of bone antiresorptive activity. Phosphorus, Sulfur Silicon 109/110:217-220.
76. van Beek E, Löwik C, Oue I, Papapoulos S 1996 Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Miner Res 11:1492-1497.
77. Adami S, Zamberlan N 1996 Adverse effects of bisphosphonates. Drug Safety 14:158-170.
78. van Staa TP 1998 Post marketing survey with ICT-etidronate therapy. Rev Contemporary Pharmacology 9:277-286.
79. DeGroen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK 1996 Esophagitis associated with the use of alendronate. N Engl J Med 355:1016-1021.
80. Coukell AJ, Markham A 1998 Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging 12:149-168.
81. Singer FR, Clemens TL, Eusebio RE, Bekker PJ 1998 Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J Clin Endocrinol Metab 83:1906-1910.
82. Sins ES, Chines AA, Altman RD, Brown JP, Johnston CC, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ 1998 Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study. J Bone Miner Res 13:1032-1038.
83. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, Zhang D, Barbier A, Suda T 1995 A possible mechanism of the specific action of bisphosphonates on osteoclasts: Tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17:137-144.
84. Hughes DE, MacDonald BR, Russell RGG, Gowen M 1989 Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83:1930-1935.
85. Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MLL, Wil Thesing C, Bijvoet OLM 1986 Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1:27-39.
86. Löwik CWGM, van der Pluijm G, van der Wee-Pals LJA, Bloys van Treslong-de Groot H, Bijvoet OLM 1988 Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: The effect of a bisphosphonate. J Bone Miner Res 3:185-192.
87. Sahni M, Guenther H, Fleisch H, Collin P, Martin TJ 1993 Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004-2011.
88. Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugai N, Yamamoto M, Nagata N 1996 Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18:9-14.
89. Yu X, Scholler J, Foged NT 1996 Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106. Bone 19:339-345.
90. Vitte C, Fleisch H, Guenther HL 1996 Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137:2324-2333.
91. Suda T, Nakamura I, Jimi E, Takahashi N 1997 Regulation of osteoclast function. J Bone Miner Res 12:869-879.
92. Masarachia P, Weinreb M, Balena R, Rodan GA 1996 Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19:281-290.
93. Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki M 1995 Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 16:235-245.
94. Sato M, Grasser W 1990 Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 5:31-40.
95. 2MBP-coated bone. Bone Miner 6:33-43.
96. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA 1991 Bisphosphonate action. Alendronate localisation in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105.
97. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran H, Rodan SB, Rodan GA 1995 Alendronate inhibition of protein tyrosine phosphatase activity. Proc Natl Acad Sci USA 93:3068-3073.
98. Endo N, Rutledge SJ, Opas EE, Vogel R, Rodan GA, Schmidt A 1996 Human protein tyrosine phosphatases: Alternative splicing and inhibition by bisphosphonates. J Bone Miner Res 11:535-543.
99. Olpas EE, Rutledge SJ, Golub E, Stern A, Zimolo Z, Rodan GA, Schmidt A 1997 Alendronate inhibition of protein-tyrosine-phosphatase-Meg1. Biochem Pharmacol 54:721-727.
100. Murakami H, Takahashi N, Tanaka S, Nakamura I, Udagawa N, Nakajo S, Nakaya K, Abe M, Yuda Y, Konno F, Barbier A, Suda T 1997 Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone 20:399-404.
101. + ATPase. J Bone Miner Res 11:1498-1507.
102. Carano A, Teitelbaum SA, Konsek JD, Schlesinger PH, Blair HC 1990 Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85:456-461.
103. Zimolo Z, Wesolowski G, Rodan GA 1995 Acid extrusion is induced by osteoclast attachment to bone. J Clin Invest 96:2277-2283.
104. Felix R, Russell RGG, Fleisch H 1976 The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Acta 429:429-438.
105. Lerner UH, Larsson A 1987 Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro. Bone 8:179-189.
106. Ito M, Chokki M, Ogino Y, Satomi Y, Azuma Y, Ohta T, Kiyoki M 1998 Comparison of the cytotoxic effects of bisphosphonates in vitro and in vivo. Calcif Tissue Int 63:143-147.
107. Breuil V, Cosman F, Stein L, Horbert W, Nieves J, Shen V, Lindsay R, Dempster DW 1998 Human osteoclast formation and activity in vitro: Effects of alendronate. J Bone Miner Res 13:1721-1729.
108. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF 1995 Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487.
109. Selander KS, Mönkkönen J, Karhukorpi E-K, Härkönen P, Hannuniemi R, Väänänen HK 1996 Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 50:1127-1138.
110. Rogers MJ, Chilton KM, Coxon F, Lawry J, Smith MO, Suri S, Russell RGG 1996 Bisphosphonates induce apoptosis in mouse macrophage-like cells by a nitric-oxide-independent mechanism. J Bone Miner Res 11:1482-1491.
111. Coxon FP, Benford HL, Russell RGG, Rogers MJ 1998 Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol 54:631-638.
112. Shipman CM, Rogers MJ, Apperley JF, Russell RGG, Croucher PJ 1997 Bisphosphonates induce apoptosis in human myeloma cells: A novel anti-tumour activity. Br J Haematol 98:665-672.
113. Shipman CM, Croucher PI, Russell RGG, Rogers MJ 1998 The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58:5294-5297.
114. Plotkin LI, Bellido T, Bonewald L, Papapoulos SE, Jilka RL, Manolagas SC 1998 Bisphosphonates prevent glucocorticoid-induced apoptosis of human myeloma cells in vitro: A putative mechanism influencing mechanosensing. Bone 23:S157.
115. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274-282.
116. Rogers MJ, Watts DJ, Russell RGG, Ji X, Xiong X, Blackburn GM, Bayless A, Ebetino FH 1994 Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mould Dictyostelium discoideum. J Bone Miner Res 9:1029-1039.
117. Rogers MJ, Xiong X, Brown RJ, Watts DJ, Russell RG, Bayless AV, Ebetino FH 1995 Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol Pharmacol 47:398-402.
118. Rogers MJ, Ji X, Russell RGG, Blackburn GM, Williamson MP, Bayless AV, Ebetino FH, Watts DJ 1994 Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem J 303:303-311.
119. Rogers M, Russell RGG, Blackburn GM, Williamson MP, Watts DJ 1992 Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. Biochem Biophys Res Commun 189:414-423.
120. Rogers MJ, Brown RJ, Hodkin V, Russell RGG, Watts DJ 1996 Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 224:863-869.
121. Pelorgeas S, Martin J-P, Satre M 1992 Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum. Biochem Pharmacol 44:2157-2163.
122. Frith JC, Mönkkönen J, Blackburn GM, Russell RGG, Rogers MJ 1996 Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-B,G-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358-1367.
123. Auriola S, Frith J, Rogers MJ, Koivuniemi A, Mönkkönen J 1997 Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J Chrom B 704:187-195.
124. Frith JC, Coxon FP, Auriola S, Monkkonen J, Yu X, Scheven B, Russell RGG, Rogers MJ 1998 The molecular mechanism of action of clodronate in osteoclasts. J Bone Miner Res 23 (Suppl):S551.
125. Rogers MJ, Xiong X, Ji X, Mönkkönen J, Russell RGG, Blackburn GM, Williamson MP, Watts DJ 1997 Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonates is dependent on cellular uptake. Pharm Res 14:625-630.
126. Zhang FL, Casey PJ 1996 Protein prenylation: Molecular mechanisms and functional consequences. Ann Rev Biochem 65:241-269.
127. Ridley AJ, Hall A 1992 The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70:389-399.
128. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A 1992 The small GTP-binding protein, rac, regulates growth factor-induced membrane ruffling. Cell 70:401-410.
129. Zerial M, Stenmark H 1993 Rab GTPases in vesicular transport. Curr Opin Cell Biol 5:613-620.
130. Zhang D, Udagawa N, Nakamura I, Murakami H, Saito S, Yamasaki K, Shibasaki Y, Morii N, Narumiya S, Takahashi N, Suda T 1995 The small GTP-binding protein, Rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci 108:2285-2292.
131. Marshall C 1993 Protein prenylation: A mediator of protein-protein interactions. Science 259:1865-1866.
132. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ 1998 Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581-589.
133. Luckman SP, Coxon FP, Ebetino FH, Russell RGG, Rogers MJ 1998 Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13:1668-1678.
134. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RGG, Rodan GA, Reszka AA 1999 Mechanism of action of alendronate: geranylgeraniol, an intermediate of the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA 96:133-138.
135. Hall A 1998 Rho GTPases and the actin cytoskeleton. Science 279:509-514.
136. Amin D, Cornell SA, Perrone MH, Bilder GE 1996 1-hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Drug Res 46:759-762.
137. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH 1992 Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657-1663.
138. van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S 1999 Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Comms 255:491-494.
139. Sauty A, Pecherstorfer M, Zimmerroth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud D 1996 Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonate treatment in vitro and in patients with malignancy. Bone 18:133-139.
140. Schweitzer DH, Oostendorp-van de Ruit M, van der Pluijm G, Löwik CWGM, Papapoulos SE 1995 Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 10:956-962.
141. Adami S, Zamberlan N 1996 Adverse effects of bisphosphonates. Drug Safety 14:158-170.
142. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Savagno G, Lo Cascio V 1987 The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41:326-331.
143. Mee AP 1999 Paramyxoviruses and Paget's disease: The affirmative view. Bone 24:19S-21S.